Spontaneous mutants of staphylococcal polyvalent bacteriophages
with broad lytic host-range on Staphylococcus aureus strains
are suitable for phage therapy

D 2017

Spontaneous mutants of staphylococcal polyvalent bacteriophages with broad lytic host-range on Staphylococcus aureus strains are suitable for phage therapy

DOŠKAŘ, Jiří, Tibor BOTKA, Renata KARPÍŠKOVÁ, IVANA KOLÁČKOVÁ, Ivana MAŠLAŇOVÁ et. al.

Basic information

Original name

Spontaneous mutants of staphylococcal polyvalent bacteriophages with broad lytic host-range on Staphylococcus aureus strains are suitable for phage therapy

Authors

DOŠKAŘ, Jiří, Tibor BOTKA, Renata KARPÍŠKOVÁ, IVANA KOLÁČKOVÁ, Ivana MAŠLAŇOVÁ, Vladislava RŮŽIČKOVÁ and Roman PANTŮČEK

Edition

1st German Phage Symposium, p. 87, 2017

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

Genetics and molecular biology

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Organization unit

Faculty of Science

Keywords in English

Bacteriophage; Spontaneous mutants; Specialized collections; Staphylococcus aureus; MRSA

Abstract

V originále

Due to a high lytic activity and broad host range towards Staphylococcus aureus strains, the polyvalent Twort-like bacteriophages of genus Kayvirus, family Myoviridae represented by phage 812 are already used for phage therapy in the Czech Republic. From this phage spontaneous mutants can be isolated as rare plaques on resistant staphylococcal strains. Recently 15 phage mutants were characterized on genomic, proteomic and structural level. We determined their lytic effect on a set of 200 human and livestock-associated MRSA isolates. Phage 812 or its mutants were able to lyse 97 % of the MRSA livestock strains and 86 % of human MRSA strains. The lytic effect is preserved also in phage cocktails, therefore the novel mutants could be used for innovation of recent phage preparations in order to increase their effect on currently circulating strains. To assess the safety of phage 812 mutants for phage therapy, complete genome sequences were determined and compared to the wild-type phage 812. We have found that the mutants differ from the original genome mostly by short indels. Mutations seem to affect the host range in two ways: either interfere with adsorption genes (tail-fibre) and lysis (endolysin), or affect sequences that are the target of bacterial defence mechanisms such as RM-systems or CRISCP-Cas. Mutations do not induce lysogenic conversion and transduction nor virulence factors production. Therefore, the mutants thus obtained can be considered safe for phage therapy. Acknowledgement: Research was supported by a grant of Ministry of Agriculture of the Czech Republic No. QJ1510216.

Links

QJ1510216, research and development project

Name: Fágová terapie infekcí vyvolaných Staphylococcus aureus v chovech hospodářských zvířat (Acronym: StafyFag)

Investor: Ministry of Agriculture of the CR

Citovat

DOŠKAŘ, Jiří, Tibor BOTKA, Renata KARPÍŠKOVÁ, IVANA KOLÁČKOVÁ, Ivana MAŠLAŇOVÁ, Vladislava RŮŽIČKOVÁ and Roman PANTŮČEK. Spontaneous mutants of staphylococcal polyvalent bacteriophages with broad lytic host-range on Staphylococcus aureus strains are suitable for phage therapy. In University of Hohenheim, Research Center for Heath Sciences. 1st German Phage Symposium. 2017, p. 87.

@inproceedings{1400639,
   author = {Doškař, Jiří and Botka, Tibor and Karpíšková, Renata and KOLÁČKOVÁ, IVANA and Mašlaňová, Ivana and Růžičková, Vladislava and Pantůček, Roman},
   booktitle = {1st German Phage Symposium},
   editor = {University of Hohenheim, Research Center for Heath Sciences},
   keywords = {Bacteriophage; Spontaneous mutants; Specialized collections; Staphylococcus aureus; MRSA},
   language = {eng},
   note = {Nepřenášíme do RIV, výsledek má jen 1 stranu, podle metodiky M17+ musí mít stať ve sborníku min. 2 strany.},
   pages = {87},
   title = {Spontaneous mutants of staphylococcal polyvalent bacteriophages with broad lytic host-range on Staphylococcus aureus strains are suitable for phage therapy},
   url = {https://1st-german-phage-symposium.uni-hohenheim.de/en},
   year = {2017}
}

TY  - JOUR
ID  - 1400639
AU  - Doškař, Jiří - Botka, Tibor - Karpíšková, Renata - KOLÁČKOVÁ, IVANA - Mašlaňová, Ivana - Růžičková, Vladislava - Pantůček, Roman
PY  - 2017
TI  - Spontaneous mutants of staphylococcal polyvalent bacteriophages with broad lytic host-range on Staphylococcus aureus strains are suitable for phage therapy
N1  - Nepřenášíme do RIV, výsledek má jen 1 stranu, podle metodiky M17+ musí mít stať ve sborníku min. 2 strany.
KW  - Bacteriophage
KW  - Spontaneous mutants
KW  - Specialized collections
KW  - Staphylococcus aureus
KW  - MRSA
UR  - https://1st-german-phage-symposium.uni-hohenheim.de/en
N2  - Due to a high lytic activity and broad host range towards Staphylococcus aureus strains, the polyvalent Twort-like bacteriophages of genus Kayvirus, family Myoviridae represented by phage 812 are already used for phage therapy in the Czech Republic. From this phage spontaneous mutants can be isolated as rare plaques on resistant staphylococcal strains. Recently 15 phage mutants were characterized on genomic, proteomic and structural level. We determined their lytic effect on a set of 200 human and livestock-associated MRSA isolates. Phage 812 or its mutants were able to lyse 97 % of the MRSA livestock strains and 86 % of human MRSA strains. The lytic effect is preserved also in phage cocktails, therefore the novel mutants could be used for innovation of recent phage preparations in order to increase their effect on currently circulating strains. To assess the safety of phage 812 mutants for phage therapy, complete genome sequences were determined and compared to the wild-type phage 812. We have found that the mutants differ from the original genome mostly by short indels. Mutations seem to affect the host range in two ways: either interfere with adsorption genes (tail-fibre) and lysis (endolysin), or affect sequences that are the target of bacterial defence mechanisms such as RM-systems or CRISCP-Cas. Mutations do not induce lysogenic conversion and transduction nor virulence factors production. Therefore, the mutants thus obtained can be considered safe for phage therapy. Acknowledgement: Research was supported by a grant of Ministry of Agriculture of the Czech Republic No. QJ1510216.
ER  -

Detailed Information on Publication Record